Lack of correlation between Treg quantification assays in inflammatory bowel disease patients

Table 1 Regulatory T-cells percentages obtained by both flow cytometry and real-time PCR methods in 35 patients with inflammatory bowel disease

Subjects	n	Age (yr)	Flow cytometry (%)	qPCR (%)	r	P value
		Average ± SD	Average ± SD	Average ± SD
Patients with Crohn´s disease	18	38 ± 10	1.62 ± 0.62	1.05 ± 0.56	-0.10	0.68
Female	10	39 ± 11	1.44 ± 0.66	1.00 ± 0.70	-0.18	0.61
Male	8	37 ± 9	1.83 ± 0.53	1.12 ± 0.35	-0.30	0.47
Patients with ulcerative colitis	17	43 ± 17	1.50 ± 0.93	1.10 ± 0.52	-0.05	0.85
Female	8	45 ± 14	1.39 ± 0.63	0.99 ± 0.45	-0.06	0.89
Male	9	41 ± 20	1.60 ± 1.17	1.19 ± 0.58	-0.03	0.93
Current drug therapy
Infliximab	4	46 ± 11	1.65 ± 0.97	0.98 ± 0.34	0.20	0.80
Azathiaprine	14	41 ± 18	1.57 ± 0.81	1.07 ± 0.60	-0.21	0.48
Systemic corticosteroids	9	39 ± 12	1.73 ± 0.98	0.91 ± 0.40	-0.06	0.88

Data stratification: patients with Crohn´s disease and ulcerative colitis, as well as applied drug therapy. Correlation coefficients (r) and respective P values were calculated according to Spearman Rho.